Documents

Three phase 2 studies fully funded, targeting high-value markets in liver cancer and rare bone diseases.

Three phase II studies fully funded, with strong clinical progress and robust cash position.

Fostrox delivers best-in-class efficacy in 2nd-line HCC, with a robust rare disease pipeline.

Strong clinical progress and improved financials, with key studies advancing and robust cash reserves.

Major clinical and financial advances position key programs for first-to-market leadership in high-need areas.

Fostrox + Lenvima delivers superior efficacy and safety in 2nd line advanced HCC, targeting a $2.5bn market.

Pipeline expansion, clinical progress, and robust funding position drive optimistic outlook.

Fostrox + Lenvima delivers superior efficacy in 2nd line HCC, targeting a $2.5bn market by 2030.

Fostrox + Lenvima delivers superior efficacy in advanced HCC, targeting a major unmet need.

Fostrox + Lenvima delivers strong efficacy in advanced HCC, filling a major second-line treatment gap.

Fostrox + Lenvima delivers superior efficacy in advanced HCC, targeting a $2.5bn+ market.

Phase II trial for a first-in-class liver cancer therapy targets a $3B second-line market.

Rights issue to fund fostrox phase II; Remetinostat outlicensed; Q3 loss and cash flow improved.

Fostrox + Lenvima demonstrates superior efficacy in 2nd line HCC and advances toward global approval.

Strong clinical results and patent gains position fostrox plus Lenvima as a second-line HCC leader.

Encouraging liver cancer study results, extended patent, and phase IIb prep pending funding.

Fostrox + Lenvima delivers promising results in advanced HCC, advancing to global phase 2b trial.